Predicting the outcome of ankylosing spondylitis therapy

Annals of the Rheumatic Diseases

Volumn 70, Issue 6, 2011, Pages 973-981

  Vastesaeger, Nathan ^a,b   Van Der Heijde, Désirée ^c   Inman, Robert D ^d   Wang, Yanxin ^a,b   Deodhar, Atul ^e   Hsu, Benjamin ^f   Rahman, Mahboob U ^f,g   Dijkmans, Ben ^h   Geusens, Piet ⁱ   Cruyssen, Bert Vander ^j   Collantes, Eduardo ^k   Sieper, Joachim ^l   Braun, Jürgen ^m  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Currently Merck   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TORONTO   (Canada)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f CENTOCOR INC   (United States)

^g PFIZER INC   (United States)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ HASSELT UNIVERSITY   (Belgium)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m RHEUMAZENTRUM RUHRGEBIET   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

AGE; ALGORITHM; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTICLE; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX SCORE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; EFFECT SIZE; ENTHESITIS; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT DURATION;

ADULT; AGE FACTORS; ALGORITHMS; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; EPIDEMIOLOGIC METHODS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-B27 ANTIGEN; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROGNOSIS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955816720     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.147744     Document Type: Article

References (33)

1. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65 : 442-52.
2. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006 ; 65 : 316-20. (Pubitemid 43268219) (Pubitemid 43268219)
3. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003 ; 48 : 3230-6. (Pubitemid 37409337) (Pubitemid 37409337)
4. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebocontrolled, phase III trial. Arthritis Rheum 2008 ; 58 : 3402-12.
5. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 ; 52 : 582-91. (Pubitemid 40216323) (Pubitemid 40216323)
6. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006 ; 54 : 2136-46. (Pubitemid 44051069) (Pubitemid 44051069)
7. Gossec L, Dougados M, Phillips C, et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 2008 ; 67 : 782-8. (Pubitemid 351829378) (Pubitemid 351829378)
8. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004 ; 63 : 665-70. (Pubitemid 38658395) (Pubitemid 38658395)
9. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009 ; 61 : 1484-90.
10. Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010 ; 69 : 2002-8.
11. Lord PA, Farragher TM, Lunt M, et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010 ; 49 : 563-70.
12. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009 ; 36 : 801-8.
13. Stone MA, Payne U, Pacheco-Tena C, et al. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004 ; 63 : 84-7. (Pubitemid 38064609) (Pubitemid 38064609)
14. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008 ; 67 : 511-17. (Pubitemid 351498433) (Pubitemid 351498433)
15. Vander Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007 ; 66 : 1072-7. (Pubitemid 47122322) (Pubitemid 47122322)
16. Smith MD, Ahern MJ. Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based? Intern Med J 2006 ; 36 : 72-6. (Pubitemid 43287318) (Pubitemid 43287318)
17. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 ; 21 : 2286-91.
18. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 ; 44 : 1876-86. (Pubitemid 32758236) (Pubitemid 32758236)
19. Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009 ; 68 : 18-24.
20. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009 ; 68 : 1811-18.
21. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011 ; 70 : 47-53.
22. Tape TG. Interpreting diagnostic tests: ROC curves - the area under an ROC curve. http://gim.unmc.edu/dxtests/ROC3.htm. (accessed 25 Jan 2010).
23. Hosmer DW, Lemeshow S. Applied logistic regression, 2nd edn. Hoboken, NJ : John Wiley & Sons, 2000.
24. Rosenthal JA. Qualitative descriptors of strength of association and effect size. J Soc Serv Res 1996 ; 21 : 37-59.
25. Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009 ; 48 : 1114-21.
26. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ : Lawrence Erlbaum Associates, 1988.
27. Collantes E, Zarco P, Muñoz E, et al. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford) 2007 ; 46 : 1309-15. (Pubitemid 47244507) (Pubitemid 47244507)
28. Vander Cruyssen B, Muñoz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 2010 ; 49 : 73-81.
29. Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise - the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007 ; 34 : 1740-5. (Pubitemid 47267619) (Pubitemid 47267619)
30. Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009 ; 68 : 948-53.
31. Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum 2004 ; 51 : 154-9. (Pubitemid 38468696) (Pubitemid 38468696)
32. Song IH, Rudwaleit M, Listing J, et al. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 2009 ; 68 : 1701-7.
33. Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008 ; 67 : 1276-81.